Subscribe To
CHE / Buy Chemed To Reduce Equity Beta And Stabilize Portfolio Returns
CHE News
By Zacks Investment Research
October 27, 2023
Chemed (CHE) Q3 Earnings and Revenues Surpass, Margins Rise
Chemed's (CHE) third-quarter 2023 performance reflects strength in the VITAS segment. more_horizontal
By Seeking Alpha
October 26, 2023
Chemed Corporation (CHE) Q3 2023 Earnings Call Transcript
Chemed Corporation (NYSE:CHE ) Q3 2023 Earnings Conference Call October 26, 2023 10:00 AM ET Company Participants Holley Schmidt - Assistant Controlle more_horizontal
By Zacks Investment Research
October 25, 2023
Chemed (CHE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Chemed (CHE) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to com more_horizontal
By Zacks Investment Research
October 25, 2023
Chemed (CHE) Q3 Earnings and Revenues Beat Estimates
Chemed (CHE) came out with quarterly earnings of $5.32 per share, beating the Zacks Consensus Estimate of $4.92 per share. This compares to earnings o more_horizontal
By Zacks Investment Research
October 20, 2023
OPCH or CHE: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Outpatient and Home Healthcare sector have probably already heard of Option Care (OPCH) and Chemed ( more_horizontal
By InvestorPlace
September 25, 2023
3 Mighty Mid-Cap Stocks Ready to Shine This Fall
In the current market cycle, where inflation is sticky and central banks weigh their next move, some investors need help choosing which type of stocks more_horizontal
By Zacks Investment Research
September 18, 2023
DVA or CHE: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with DaVita HealthCare (DVA) and Chemed (CHE). But which o more_horizontal
By Zacks Investment Research
September 14, 2023
Chemed (CHE) Faces Macroeconomic Woes, Tough Competition
Inflationary trend, increased logistics costs and higher employee-related expenses continue to hurt Chemed's (CHE) growth. more_horizontal